[go: up one dir, main page]

CA2386411A1 - Utilisation de comme inhibiteurs de la caspase-3 nicotinyl aspartyl ketones as inhibitors of caspase-3 - Google Patents

Utilisation de comme inhibiteurs de la caspase-3 nicotinyl aspartyl ketones as inhibitors of caspase-3 Download PDF

Info

Publication number
CA2386411A1
CA2386411A1 CA002386411A CA2386411A CA2386411A1 CA 2386411 A1 CA2386411 A1 CA 2386411A1 CA 002386411 A CA002386411 A CA 002386411A CA 2386411 A CA2386411 A CA 2386411A CA 2386411 A1 CA2386411 A1 CA 2386411A1
Authority
CA
Canada
Prior art keywords
3alkyl
6alkyl
aryl
hetcy
4alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002386411A
Other languages
English (en)
Inventor
Cameron Black
Erich L. Grimm
Elise Isabel
Johanne Renaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Frosst Canada and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2386411A1 publication Critical patent/CA2386411A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés inhibiteurs de la caspase-3 représentés par la formule générale (I), ainsi que des compositions pharmaceutiques et des méthodes de traitement. Lesdits composés sont utiles dans le traitement de maladies et d'états induits par la caspase-3, parmi lesquelles les ischémies cardiaques ou cérébrales ou les lésions dues à une reperfusion, le diabète type 1, le syndrome d'immunodéficience, y compris le SIDA, les lésions cérébrales et les traumatismes médullaires, les dommages subits par des organes lors d'une greffe, l'alopécie, le vieillissement, la maladie de Parkinson, la maladie d'Alzheimer, le syndrome de Down, la maladie d'Aran-Duchenne, la sclérose en plaques et les troubles neurodégénératifs.
CA002386411A 1999-10-13 2000-10-11 Utilisation de comme inhibiteurs de la caspase-3 nicotinyl aspartyl ketones as inhibitors of caspase-3 Abandoned CA2386411A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15934899P 1999-10-13 1999-10-13
US60/159,348 1999-10-13
PCT/CA2000/001196 WO2001027085A1 (fr) 1999-10-13 2000-10-11 Utilisation de comme inhibiteurs de la caspase-3 nicotinyl aspartyl ketones as inhibitors of caspase-3

Publications (1)

Publication Number Publication Date
CA2386411A1 true CA2386411A1 (fr) 2001-04-19

Family

ID=22572201

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002386411A Abandoned CA2386411A1 (fr) 1999-10-13 2000-10-11 Utilisation de comme inhibiteurs de la caspase-3 nicotinyl aspartyl ketones as inhibitors of caspase-3

Country Status (3)

Country Link
AU (1) AU7766900A (fr)
CA (1) CA2386411A1 (fr)
WO (1) WO2001027085A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878743B2 (en) 2001-09-18 2005-04-12 Sunesis Pharmaceuticals, Inc. Small molecule inhibitors of caspases
WO2004014843A1 (fr) * 2002-08-09 2004-02-19 Takeda Chemical Industries, Ltd. Composés amino substitués et utilisation de ces composés
WO2007011760A2 (fr) * 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibiteurs de la kinesine mitotique
IT1392238B1 (it) * 2008-12-02 2012-02-22 Fond Santa Lucia Uso della caspasi-3 per la malattia dell'alzheimer
JP7199411B2 (ja) * 2018-02-26 2023-01-05 日本化薬株式会社 塩基増殖剤及び当該塩基増殖剤を含有する塩基反応性樹脂組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2237314A1 (fr) * 1996-09-12 1998-03-19 Donald S. Karanewsky Nouveaux composes tricycliques permettant d'inhiber la famille de proteases ice/ced-3
WO1999047154A1 (fr) * 1998-03-16 1999-09-23 Cytovia, Inc. Dipeptides inhibiteurs de caspase et leur utilisation
BRPI9909660B8 (pt) * 1998-03-19 2021-05-25 Vertex Pharma compostos inibidores de caspases, composição farmacêutica e uso de ditos compostos

Also Published As

Publication number Publication date
WO2001027085A1 (fr) 2001-04-19
AU7766900A (en) 2001-04-23

Similar Documents

Publication Publication Date Title
US6225288B1 (en) Gamma-ketoacid dipeptides as inhibitors of caspase-3
US6399627B1 (en) Inhibitors of factor Xa
CA2378834C (fr) Pyrazinones, compositions contenant ces composes
OA10764A (en) Protease inhibitors
US20030114447A1 (en) Small molecule inhibitors of caspases
JPH05279319A (ja) 新規なスルホンアミド誘導体、その製造方法及びこれを含有する医薬
KR20010030945A (ko) 펩티드 함유 α-케토아미드 시스테인 및 세린 프로테아제억제제
US6686368B1 (en) Inhibitors of factor Xa
KR20010005940A (ko) 메탈로프로테이나제 억제제를 포함하는 약제학적 조성물 및 이의 약제학적 용도
CA2386411A1 (fr) Utilisation de comme inhibiteurs de la caspase-3 nicotinyl aspartyl ketones as inhibitors of caspase-3
US6552168B1 (en) Gamma-ketoacid tetrapeptides as inhibitors of caspase-3
CA2198366A1 (fr) Nouvelles 4-aminopyridazines; methode de preparation et agents pharmaceutiques a base de ces composes
US6525025B2 (en) Gamma-ketoacid dipeptides as inhibitors of caspase-3
US20030045478A1 (en) Gamma-ketoacid dipeptide derivatives as inhibitors of caspase-3
US20020077455A1 (en) Protease inhibitors
CZ393499A3 (cs) Inhibitory proteasy

Legal Events

Date Code Title Description
FZDE Dead